TITLE

Two Steps Forward

AUTHOR(S)
Egan, Mary Ellen
PUB. DATE
September 2008
SOURCE
Forbes Asia;9/1/2008, Vol. 4 Issue 14, p76
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the drug called Dirucotide, a chain of 17 amino acids that treats multiple sclerosis in the U.S. The introduction of Dirucotide by doctors Kenneth Warren and Ingrid Catz at the University of Alberta, is very promising for the management and treatment of the disease. Moreover, the drug is subject for approval by the U.S. Food and Drug Administration.
ACCESSION #
34379548

 

Related Articles

  • Cladribine Falters, Biotech MS Candidates Move Up. Shaffer, Catherine // BioWorld Today;3/3/2011, Vol. 22 Issue 42, p1 

    This article reports on the setbacks facing EMD Serono Inc. with its cladribine tablets for relapsing and remitting multiple sclerosis (MS) amid growing competition from companies such as Novartis AG. The MS market is dominated by Avonex, Betaseron, Copaxone and Rebif. Particular focus is given...

  • Opexa's Tovaxin for the Treatment of Multiple Sclerosis Granted Fast Track Designation by FDA.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p601 

    The article reports on the revelation of Opexa Therapeutics Inc. that its lead drug candidate Tovaxin is granted with Fast Track designation by Food and Drug Administration (FDA) for the treatment of patients with secondary progressive multiple sclerosis (SPMS) in the U.S. It states that the...

  • Sanofi: Lemtrada will emerge as a key MS therapy if concerns are addressed.  // PharmaWatch: CNS;Aug2011, Vol. 10 Issue 8, p5 

    The article offers updates on the development of Lemtrada, a drug for multiple sclerosis treatment from drugmaker Sanofi-Aventis SA. It notes that the Phase III clinical study of the drug shows that the drug is more effective in reducing relapses than interferons but depicts uncertainty in...

  • XenoPort submits IND application for multiple sclerosis drug.  // PharmaWatch: CNS;Jul2012, Vol. 11 Issue 7, p7 

    The article reports on the investigational new drug (IND) application filed by XenoPort Inc. to U.S. Food and Drug Administration (FDA) to start clinical studies on XP23829 as treatment for relapsing-remitting multiple scleroris (RRMS). It states that the clinical studies will focus on safety,...

  • Betaseron approved for secondary-progressive MS.  // Inside MS;Jul-Sep2003, Vol. 21 Issue 3, p29 

    Announces that the U.S. Food and Drug Administration (FDA) has approved revised labeling of Betaseron or interferon beta-1b to extend its use to treat people with relapsing forms of multiple sclerosis (MS). Influence of the clinical trials of Betaseron in people with secondary-progressive MS on...

  • Sanofi/Genzyme: modest efficacy sees Aubagio compete on price.  // PharmaWatch: CNS;Nov2012, Vol. 11 Issue 11, p5 

    The article reports on the move by the U.S. Food and Drug Administration (FDA) to approve the drug Aubagio (teriflunomide) from Sanofi as an oral treatment for relapsing multiple sclerosis (MS). The decision was made based on the results of the pivotal Phase III Teriflunomide Multiple Sclerosis...

  • XenoPort Submits Investigational New Drug Application for XP23829 as a Potential Treatment of RRMS.  // Biomedical Market Newsletter;6/1/2012, Vol. 21, p1 

    The article informs that XenoPort Inc. has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate the clinical study of XP23829 as a potential treatment for relapsing-remitting multiple sclerosis (RRMS). This clinical study will be...

  • New biologic offers hope for MS patients. LoBuono, Charlotte // Drug Topics;1/10/2005, Vol. 149 Issue 1, p17 

    The Food and Drug Administration (FDA) recently granted expedited approval for natalizumab to reduce the frequency of clinical exacerbations in those with the relapsing forms of multiple sclerosis (MS). The FDA granted expedited approval based on the first-year safety and efficacy data from two...

  • Vascular Expert Supports FDA Warning about Experimental Therapy for MS Patients.  // Biomedical Market Newsletter;5/18/2012, Vol. 21, p1 

    The article presents information that Barry Katzen, founder and medical director of Baptist Cardiac & Vascular Institute in Miami, is advocating a controlled clinical trial related to treatment of chronic cerebrospinal venous insufficiency for multiple sclerosis. Information on a warning issued...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics